Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Elsie that’s hilarious. All your things that would never happen. Oh look they won’t get approval approvals on deck
It took many more years than normal.
-NWBIO will never data lock
According to their own website the trial is still ongoing. LOL. It took twenty years to run with still unknown reaction from regulators for changing the design to an external control.
-They will never finish the trial
Dragged out for years. Data isn't solid.
-They will never release results
I admit JAMA surprised me. Thought it'd be that Italian journal they reported in previously. The JAMA pub hasn't gone without controversy, however. Also JAMA notes only Bosch responsible for the data.
-They will never get published
They did but only after tiny MHRA umbilical cord was cut from EMA. And, management was rewarded handsomely for submittal but not approval. We'll see in the fall.
-They will never apply for approvals
Boiler room boy is to put emojis on all negative posts and then login with his other aliases and do the same emojis. Pathetic.
No- it’s a constantly shifting FUD narrative he and others like him are paid to continue to push, in hopes of influencing new board viewers.
Just look at all the arguments they’ve had to give up, as they move on to the next- there’s only a few more arguments available, and each is more feeble than the last.
-NWBIO will never data lock
-They will never finish the trial
-They will never release results
-They will never get published
-They will never apply for approvals
I ask you the simplest question to define "Lots" from your initial statement but you could not do it.
lol denial .. your just tired of getting slammed with every stupid comment u make ..
and u get paid by the response
BASHERS never block people
Thats what I thought too - you’re a paid short. You don’t care about patients and their families. Tell them they will not only save money but also not be able to enroll in a free trial in the future. You can do a lot of good there, LC!
Tell that to patients families too. Start with one, LC!
Your time and energy better spent there. You will also save their families a lot of money!
You're in total denial. I'm going to have to ignore you. Sorry.
They have not wasted time ..
U and your friends have delayed them at every turn
But it appears to be for the better for current shareholders .. yes there is a legacy of skeleton shareholders along the way .. thanks to u n your bash bros
Yep, that's what I thought. It's too embarrassing to think about.
LOL. One trial redo or required confirmatory and you've got a half dozen treatments for GBM in the race. And, at the pace this crew moves they'll be overtaken - Already being overtaken with so much time wasted.
>>pretend like they are a threat to DC VAX.
Take baby steps and start with one or two.
Yes
It explains I have far more basis than you do …
Paid for a year of college
Provided an additional job and career connections
Got published as a coauthor !!
Far more credentialed in the business than u could ever dream to be …
How are those hot pockets your eating for lunch today in moms basement. ..
U still stealing internet ??
That would explain a lot.
>>I myself participated in over 30 clinical trials. You actually get compensated for them.
It’s a shame you’ve done everything in your power to prevent patience from receiving DC VAX over the years just think of all the lives that could’ve been spared and you’ve been championing the cause for DC VAX rather than being an impediment to its approval you’re on the wrong side of that legacy
All clinical trials are free to patients. Are you just now figuring that one out. I myself participated in over 30 clinical trials. You actually get compensated for them.
Tons of compelling free trials in progress. Unfortunately those trials won't accept patients if they've had some previous treatment like L.
He won't. He has broken promises before, and will again.
Yes, they’re just at our articles on DC VAX your attempts to divert attention to pre-clinical and phase 1 trials that are nowhere near ready for mask consumption and pretend like they are a threat to DC VAX. Do you want to try that again?
You're ignoring the Nature, JAMA, and other articles / studies I've posted. Good work.
...IF a friend or loved one was ever diagnosed with GBM today, I'd likely tell them to radically change their diet, have GKRS while getting themselves into a mRNA, T cell or SurvaxM trial, and do whatever possible to avoid any heavy doses of chemo or avoid it all together.
If I ever see good data and real world OS evidence of combo L - Poly, then perhaps I'd recommend that too. But no chemo.
Yes, why don’t you come? I’ll even spring for the crab legs just to see you’re lying face bring all your friends with you too.
XLCIC and all their basher friends are participating in the highest level of white collar crime and hopefully they are arrested for it sometime soon
Ex somehow has convenient amnesia when it comes to the jam article in attempts to divert attention as far away from it as possible. If they were truly interested in helping patients, their efforts would be better directed elsewhere instead of diverting attention away from DC VAX.
DC VAX will be approved based off of its addition to the previous standard of care. And now that LC has drawn up the new playbook it will be used in combination trials over the next few years and used off label in the meantime. Your job is done Lc go home you have lost the battle and the war.
The soc is always been 5% quit trying to grow the number to 10 and pretend that there’s no difference adding DC VAX to it
If anyone would recognize a boiler room worker it would be ULC
It’s a generic atl-dc .. not OUR DCVAX
It’s like shopping at the dollar store for your electronics rather than Apple. It’s just not the same.
LC is not really concerned with helping patients regardless of what VS he tries to post every day his bailed it diverting attention away from DC VAX to other potential therapies that are in reality truly 5 to 10 years away and pretending
Their goal is to bankrupt the company to never have to cover their short positions and move on to the next company at risk. The damage is done early to a stock price and reputation after that they just hang on the ropes hoping to survive. Northwest Bill has managed to hang onand will get to the finish line of approval sometime in the next 3 to 6 months or so it appears
Once you catch them in the first lie, then you can ignore everything else they say because you know they come with an agenda so XLC Fradin all of them have a paid motive and a playbook to operate with. But every day we take another day closer to approval, and the end is in sight for long
X wannabe will never leave the board. He will always claim some loophole because he’s paid to be here in hence cannot leave and I’m sure he has a few alias that he can post under to pretend like he’s gone, but he will always be here.
It’s amazing that someone can come to a penny stock board website for over 10 years almost every single day, but not really have a real motive and claims he doesn’t get paid ..
that Dog doesn’t hunt
What for the crab legs? If I do tune in I'll hear what's relevant without needing to look in their eyes to find the truth. Eye rolls. Otherwise the ASM is just about the disciples claiming here to have a side conversation with the two lawyers.
No comment, of course.
That's because it's like LL said about not being able to patent the patients own tumor, only the process. Get it yet?
skitahoe So you agree that it would be a material event requiring PR notification of some type. But you went and posted this statement knowing a PR would be required of which we haven't seen as yet.
"I may be mistaken but I believe that a knowledgeable poster some time ago said an approval could be made without a CHM meeting. Regardless of that being true, or not, no one is addressing the fact that this may have already occurred in the April CHM meeting so we may have already passed that hurdle."
Will have to wait a while for that news flow
The most recent CHM meeting with published minutes was May 2023
The most recent OEHAG meeting with minutes was Sep 2023 meeting.
Yes, only a few drugs are mentioned because MHRA has very few new drugs that are not basically rubber stamps of EMA approvals. 8 last year.
Why don't you reach out to patient’s family and suggest some alternative therapy? Lots of them on GoFundMe pages seeking DCVAX-L for their loved ones. Your time and concern will be better directed that way than an investor forum.
That's a musician.
"King Collage"
You can want to improve people’s lives while wanting to improve your own in a capital way. Nothing wrong with that. Why do doctors charge someone for surgery? Why can’t they do it for free for their goodness of their heart? These are useless questions.
If NWBO gets approval the price will drop on their drug, Automation is key for price drops. Yet King Collage made you angry so you become a bear here makes no logical decision to me since you were never put on this immunotherapy.
But I digress, back to a relaxing weekend.
LOL. That coming from boiler boy himself, KIPK!!!
>>just because of your hatefull demeaner.
Have to agree. For the patients the allure of a therapy without grueling side effects is just too great to see the data for what it is. Perhaps if there was some identifiable subset where survival was greater.
Followers
|
1624
|
Posters
|
|
Posts (Today)
|
2
|
Posts (Total)
|
695564
|
Created
|
02/02/05
|
Type
|
Free
|
Moderators XenaLives sentiment_stocks CaptainObvious Poor Man - Doc logic JerryCampbell |
“Now this is not the end. It is not even the beginning of the end. But it is, perhaps, the end of the beginning.”
~ Winston Churchill
Stylized Dendritic Cell featured on NWBO board since 2015
- Dr. Linda Liau, PhD, MBA, Professor and Chair, Department of Neurosurgery, David Geffen School of Medicine at UCLA
Clinical Trials
DCVax®-L to Treat Newly Diagnosed GBM Brain Cancer (NCT00045968) - Phase III (Double Blind)
UK (MHRA): DCVax-L to Treat Newly Diagnosed GBM Brain Cancer (EudraCT#) 2011-001977-13
DE (Germany - PEI): DCVax-L to Treat Newly Diagnosed GBM Brain Cancer (EudraCT#) 2011-001977-13
Expanded Access Protocol for GBM Patients with Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221 (NCT02146066) (Expanded Access)
Safety and Efficacy Study of DCVax-Direct in Solid Tumors (NCT01882946) - Phase I/Phase II (Open Label)
UK Clinical Trials - Study of a Drug (DCVax®-L) to Treat Newly Diagnosed GBM Brain Cancer
EU Clinical Trials for DCVax-L - Phase III
Dendritic Cell Vaccine for Patients with Brain Tumors (NCT01204684) - Phase II - at UCLA - Randomized (Open Label) testing DCVaccine with Resiquimod and DC Vaccination with Adjuvant polyICLC
Pembrolizumab and a Vaccine (ATL-DC) for the treatment of Surgically Accessible Recurrent Glioblastoma - Phase 1 (NCT04201873)
Dendritic Cell-Autologous Lung Tumor Vaccine (DCVax-L) and Nivolumab in Treating Patients with Recurrent Glioblastoma - Phase 2 (NCT03014804)
Dendritic Cell Therapy for Brain Metastases From Breast or Lung Cancer (NCT0368765) - Phase 1 - Collaborator: Mayo Clinic
Announcement of DCVax-L and Anti-PD-1 Monoclonal Antibody (Pembrolizumab) for Patients with Liver Metastases of Primary Colorectal Carcinoma Phase 2 Trial - November 17, 2016 - University Medical Center (UMC) of the Johannes Gutenberg University of Mainz
Cognate Bioservices - Owned by Charles River Labs
Website
Company Contact Info
Investor Relations:
Les Goldman (Company) (202) 841-7909 lgoldman@nwbio.com
Sign up for Northwest email list here (hit the subscribe to email list button in the lower right)
Company Headquarters
4800 Montgomery Lane, Suite 800, Bethesda, MD 20814 (240) 497-9024
NW Bio is developing cancer vaccines designed to treat a broad range of solid tumor cancers more effectively than current treatments, and without the side effects of chemotherapy drugs. NW Bio’s proprietary manufacturing technology enables them to produce its personalized vaccine in an efficient, cost-effective manner. NW Bio has a broad platform technology for DCVax dendritic cell-based vaccines.
Their lead product, DCVax-L, is currently in a 331-patient Phase III trial for patients with newly diagnosed Glioblastoma multiforme (GBM), the most aggressive and lethal brain cancer. This trial is currently underway at 69 locations thoughout the United States, Germany and the United Kingdom. NW Bio has also conducted a Phase I/II trial with DCVax-L for late stage ovarian cancer together with the University of Pennsylvania.
Their second product, DCVax-Direct, is currently in a 60-patient Phase I/II trial for direct injection into all types of inoperable solid tumor cancers, with trials currently being conducted at both MD Anderson Cancer Center in Texas, as well as Orlando Health in Florida.
They previously received clearance from the FDA for a 612-patient Phase III trial with its third product, DCVax-Prostate, for late stage prostate cancer.
DCVAX Survival Stories & Testimonials
Alice - Metastic Merkel Cell patient from Florida - ASCO 2018
Brad Silver - GBM patient from Huntington Beach, California - ASCO 2018
Sarah Rigby - GBM patient from Hong Kong - ASCO 2018
Kristyn Power - daughter of GBM patient from Canada - ASCO 2018
Kat Charles - GBM patients from UK - ASCO 2018 - as related by her husband Jason (Kat's Cure)
Prospective patients may contact NW Bio at patients@nwbio.com
UCLA Jamil Newirth DCVax-Patient Video - 2015
Allan Butler Video - National Geographic Vice President - DCVax-Direct patient from Phase 1 Trial with Pancreatic Cancer
NWBO - Patients Sunday Dennis and Jami Newirth - Enrolled at UCLA - Vimeo, Uploaded approx. May 2015
NWBO - Vaccine Helps Keep Brain Cancer Patient Alive (Jennifer Sugioka) - NBC Channel 4, Southern California, February 24, 2015
NWBO - National Geographic's Allan Butler Stage IV Pancreatic Patient using DCVax-Direct at MD Anderson
NWBO GBM Brain Cancer Survival Story of Mark Pace
Presentations
UCLA Agreements
Prostrate
DCVax-Phase II
DCVax-Booster
Upcoming Events
Videos
Linda M. Liau, MD, PhD, MBA - April 24, 2019 at University of Washington, Neurosciences Institute
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |